Higher-income households with at least one user of GLP-1 class of weight loss drugs cut their grocery spending by nearly 9%, ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.

The rest of Europe could learn from them. Politicians in Brussels are perpetually searching for ways to invigorate the ...

Weight Loss Industry Booms as Obesity Rates Rise and GLP-1 drugs are seen as a revolutionary innovation for weight loss.

Explore 13 of the most technologically advanced countries leading in innovation, research, and technological development ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...

The proposed Biosecure Act as well as the diversification of American and European firms away from China are expected to help ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking ...